Suppr超能文献

鉴定 NBS1 表达增加可作为口腔鳞状细胞癌的预后标志物。

Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity.

机构信息

Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.

出版信息

Cancer Sci. 2010 Apr;101(4):1029-37. doi: 10.1111/j.1349-7006.2009.01471.x. Epub 2009 Dec 15.

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most prevalent cancers worldwide; however, accurate molecular markers to predict its prognosis are still limited. We previously demonstrated that overexpression of the DNA double-strand break repair protein NBS1 is a prognostic marker of advanced head and neck squamous cell carcinoma (HNSCC). Therefore, we aimed to investigate the feasibility of using NBS1 as a biomarker in OSCC. In this study, we enrolled 148 OSCC for immunohistochemical (IHC) and clinical analysis. Data from 58 advanced non-oral-cavity HNSCC (NO-HNSCC) cases were also included for comparison due to the biological and clinical discrepancy between OSCC and HNSCC originated from the other sites (e.g. pharynx or larynx). First, we validated the NBS1 IHC results by real-time RT-PCR analysis, and an excellent correlation between the results of these two assays confirmed the reliability and robustness of IHC procedures and interpretation. NBS1 overexpression was an independent prognostic marker in both OSCC and NO-HNSCC cases. In OSCC, the prognostic significance of NBS1 was shown regardless of T stage and lymph node status. Increased NBS1 expression correlated with advanced T stage and recurrence/metastasis. NBS1 overexpression correlated with the phosphorylation levels of Akt and its downstream target mammalian target of rapamycin (mTOR). These results clearly illustrate the expression profile of NBS1 in OSCC and NO-HNSCC, and highlight the role of NBS1 in HNSCC irrespective of the primary sites. It also indicates the practicability of application of NBS1 as a marker in OSCC.

摘要

口腔鳞状细胞癌 (OSCC) 是全球最常见的癌症之一;然而,能够准确预测其预后的分子标志物仍然有限。我们之前的研究表明,DNA 双链断裂修复蛋白 NBS1 的过表达是晚期头颈部鳞状细胞癌 (HNSCC) 的预后标志物。因此,我们旨在研究将 NBS1 用作 OSCC 生物标志物的可行性。在这项研究中,我们对 148 例 OSCC 进行了免疫组织化学 (IHC) 和临床分析。由于 OSCC 和源自其他部位(例如咽部或喉部)的 HNSCC 之间存在生物学和临床差异,我们还纳入了 58 例晚期非口腔腔 HNSCC (NO-HNSCC) 病例的数据进行比较。首先,我们通过实时 RT-PCR 分析验证了 NBS1 IHC 结果,这两种检测结果之间的极好相关性证实了 IHC 程序和解释的可靠性和稳健性。NBS1 过表达是 OSCC 和 NO-HNSCC 病例的独立预后标志物。在 OSCC 中,无论 T 分期和淋巴结状态如何,NBS1 的预后意义均明显。NBS1 表达增加与晚期 T 分期和复发/转移相关。NBS1 过表达与 Akt 和其下游靶标哺乳动物雷帕霉素靶蛋白 (mTOR) 的磷酸化水平相关。这些结果清楚地说明了 NBS1 在 OSCC 和 NO-HNSCC 中的表达谱,并强调了 NBS1 在 HNSCC 中的作用,而与原发部位无关。它还表明了将 NBS1 用作 OSCC 标志物的实用性。

相似文献

引用本文的文献

本文引用的文献

6
Smoking cessation and the risk of oesophageal cancer: An overview of published studies.戒烟与食管癌风险:已发表研究综述
Oral Oncol. 2006 Nov;42(10):957-64. doi: 10.1016/j.oraloncology.2006.03.007. Epub 2006 Aug 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验